The March #StemCellEvidence Alert is out! If you don't receive it free in your inbox, sign up and see this month's top ten references here: http://www.stemcellevidence.com/alerts
#BMT #leusm #mmsm #lymsm

Our illustrious Dr. @ForsbergMD@twitter.com wins the (infamous?) Spotlight Award bobblehead at our @CUHematology@twitter.com awards night. #mmsm

From our Evidence Alert this month: Stem cell mobilization yields with daratumumab and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma Chhabra et al in Transplantation and Cellular Therapy http://www.stemcellevidence.com/article/36494017
#BMT #mmsm #StemCellEvidence

Hey #mmsm: how do you do GRIFFIN when giving dara-VRd upfront? Just a quick poll. #hemetwitter

Privileged to have worked with patients who participated in the ATLAS trial with my mentors Dr. Jakubowiak and Dr. @bdermanmd@twitter.com while at @UCHemOncFellows@twitter.com, and to finally see the manuscript in print @TheLancetOncol@twitter.com! #mmsm https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00738-0/fulltext#%20

Excellent thread about BITEs in #lymsm & #mmsm by Dr. @mihematology@twitter.com. Will be very interesting to see how these settle in sequence with CAR. #celltherapy

RT @mihematology@twitter.com

I put together a talk on bispecific T cell engagers in lymphoma and myeloma for @UMNHOT@twitter.com grand rounds last week

Here’s a quick overview of the four phase 2 BiTE trials published in 2022 including:

• Glofitamab
• Epcoritamab
• Mosunetuzumab
• Teclistamab

🧵(1/7)

You see it? :-)

What a nice #MMSM on ES 5min chart today!

Cracked open my mother's clinical oncology book from 1978 (just 327 pages!). Check out the chapter on "The Malignant Lymphomas, Multiple Myeloma, and Macroglobulinemia" and all these regimens! Totally fascinating. #lymsm #mmsm

Best morning snack to begin the last day of @ASH_hematology@twitter.com #ASH22. It was great to network with all you brilliant hematologists! Please do stay in touch (and will hopefully see some of you at #ASCO23.) #lymsm #mmsm

Incredible to see continuously trending #ASH22 and related hashtags across chats/conferences/diseases/other categories! Stoked to see #lymsm #mmsm #leusm #cardiacpath #path2path #meded #lymphoma in the mix too!

RT @sanamloghavi@twitter.com

Ending #ASH22 on a high note with great friends & colleagues and amazing #IsraeliFood Thank you to all of our expert colleagues who have contributed to @HemeReports@twitter.com so far! Looking forward to more great episodes next year. #hemepath #leusm #mmsm https://www.hemereports.com

🐦🔗: https://twitter.com/sanamloghavi/status/1602521881176948738

RT @ManniMD1@twitter.com

The single MOST important study presented at #ASH22 that can impact SO many patients.
Please don’t routinely order SPEP/light chains in patients with autoimmune diseases.
Such an honor to take a picture with @ingigerdursv@twitter.com by her incredible poster
@sykristinsson@twitter.com @iStopMM@twitter.com #mmsm

🐦🔗: https://twitter.com/ManniMD1/status/1602463571216330752

MRD2STOP trial @bdermanmd@twitter.com: stop maintenance if MRD-neg at 10-6 and neg PET. 38 pts enrolled. 5 pts with MRD resurgence, 2 frankly progressed, no deaths at 15 mos f/u. Sustained MRD-neg 10-6 at 12 months = 84%. Can't wait for QOL data! #ASH22 #mmsm

So incredibly proud of Dr. @bdermanmd@twitter.com @UCCancerCenter@twitter.com on his #ASH22 presentation of the University of Chicago MRD2STOP trial of MRD-guided maintenance discontinuation in myeloma. The most important trial in which I participated during fellowship. #mmsm

RT @CyclingDoctor@twitter.com

Today @ 3:30
Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures

#ASH22 #mmsm #leusm #mdssm
@KellyLBolton@twitter.com

https://ash.confex.com/ash/2022/webprogram/Paper158992.html

🐦🔗: https://twitter.com/CyclingDoctor/status/1602308037552885761

RT @doctorpemm@twitter.com

#ASH22 🤩 Honored to meet up with our @HemeReports@twitter.com team !!! #ExpertsWithinReach | https://www.hemereports.com 🙏🏾 👏🏽 #meded #leusm #BPDCN #MPNSM #lymsm #mmsm #hemepath #pathologists

🐦🔗: https://twitter.com/doctorpemm/status/1602075331380248578

RT @profghjackson: Pre emotive toci the future prophylaxis of CRS …significant reduction in CRS and adverse impact on efficacy of cevostamab and little other adverse effects #ASH22 #mmsm …slight increase in neutropenia …increased use of GCSF 34% infection increased to 54% in the toci pre group https://t.co/IPcaprJSFf

Given EORTC QLQ-C30 MID of 6 when comparing means in #mmsm, improvements in pain and fatigue also appear meaningfully better with DRVd over time. Preserved global health & less severe tx-related side effects as well. #ASH22 #MajorPROs

RT @majorajay@twitter.com

Will do a deep dive once the manuscript is published, but the GRIFFIN QOL data looks quite good on favor of dara-VRd for multiple symptom domains. #mmsm #ASH22

Re: MAIA PRO data #ASH22: the minimally important difference in #mmsm when comparing mean changes for the EORTC QLQ-30 is 6. So, looks like pain improvement with dara-Rd is clinically meaningful, not with other domains. #MajorPROs

1/

Will do a deep dive once the manuscript is published, but the GRIFFIN QOL data looks quite good on favor of dara-VRd for multiple symptom domains. #mmsm #ASH22